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Abstract
Objective—To evaluate whether magnesium sulfate administration for neuroprotection prolongs 
latency in women with preterm premature rupture of membranes between 24 and 31 6/7 weeks' 
gestation.
Study Design—This is a secondary analysis of a randomized controlled trial of magnesium 
sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 
31 6/7 weeks' gestation with preterm premature rupture of membranes (pPROM) without evidence 
of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus 
followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for 
this analysis were delivery in less than 48 hours and in less than 7 days from randomization. 
Neonatal outcomes included a composite of respiratory distress, interventricular hemorrhage 
grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of 
prematurity, or death.
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Results—A total of 1259 women were included. The rate of delivery < 48 hours was not 
different in the magnesium sulfate and the placebo groups (22.2% and 20.7%, p=0.51). Delivery < 
7 days was similar between groups (55.4% and 51.4%, p=0.16). Median latency was also similar 
between groups (median [interquartile range] 6.0 days [2.4–13.8] and 6.6 days [2.4–15.1], p 
=0.29). Composite neonatal outcomes did not differ between groups. Conclusion: Magnesium 
sulfate administration given for neuroprotection in women with a singleton gestation with preterm 
premature rupture of membranes and without labor before 32 weeks does not impact latency.
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Introduction
Preterm premature rupture of membranes (PPROM), defined as spontaneous rupture of 
membranes before 37 weeks of gestation and the onset of contractions, affects 2–3% of 
pregnancies in the United States1 and accounts for approximately one third of all preterm 
births.2 More than 90% of gravid women who experience PPROM prior to 34 weeks deliver 
in less than one week and PPROM is a significant cause of neonatal morbidity and 
mortality.3 One of the characteristic features of PPROM is the brief time from rupture of 
membranes to delivery, with the duration of time increasing with decreasing gestational age. 
Given that neonatal morbidities are strongly correlated with gestational age at delivery, 
strategies to extend latency for those pregnancies that may benefit from the delay in delivery 
are often employed. In contemporary practice, conservative management of PPROM may 
include antibiotic administration to prolong latency, corticosteroid use to reduce prematurity 
related neonatal morbidity, and tocolytic therapy.1, 4–6
Preterm birth is a risk factor for cerebral palsy, a condition characterized by abnormal 
control of movement and posture that results in limitation of activity. Currently, one third of 
cases of cerebral palsy are associated with early preterm birth.7 Three major randomized 
clinical trials suggest that magnesium sulfate administered before an anticipated early 
preterm birth reduces the risks of cerebral palsy in surviving infants.8–10 In March 2010, the 
American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal 
Fetal Medicine released a joint clinical opinion stating that the available evidence suggests 
that magnesium sulfate is a fetal neuroprotectant. These studies included gravid women with 
heterogeneous risk factors for preterm birth and did not demonstrate significant pregnancy 
prolongation when magnesium sulfate was given for neuroprotection.11
The objective of this study was to evaluate whether magnesium sulfate administration for 
neuroprotection increases latency, specifically in women with preterm premature rupture of 
membranes between 24 and 31 6/7 weeks' gestation.
Materials and Methods
This is a secondary analysis of the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Maternal-Fetal Medicine Units Network magnesium 
sulfate trial for the prevention of cerebral palsy (BEAM trial). That study was a randomized 
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double blind placebo controlled study of 2241 women with a singleton or twin pregnancy 
between 24–31 6/7 weeks gestation at imminent risk for delivery. Full details on the study 
design, data collection, and results have previously been reported.10
Inclusion criteria for this secondary analysis included women with a singleton pregnancy 
with preterm premature rupture of membranes without evidence of labor between 24–31 6/7 
weeks’ gestation. The diagnosis of PPROM was based on documentation in the medical 
records and included the presence of ferning, vaginal pooling, and a positive nitrazine test. 
Exclusion criteria for this analysis included any of the following at the time of 
randomization: labor (defined as > 4 cm cervical dilation and ≥ 6 contractions/hour), twin 
pregnancy, suspected chorioamnionitis, previous administration of magnesium sulfate, or 
delivery within one hour after randomization. Magnesium sulfate was administered 
intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour for 12 hours if 
undelivered, or placebo. If delivery had not occurred after 12 hours and was no longer 
considered imminent, the infusion was discontinued and resumed when delivery was 
deemed imminent again (e.g., when contractions developed) until the gestational age had 
reached 34 weeks. If at least 6 hours had passed since the discontinuation of the study 
medication and retreatment was necessary, another 6-g loading dose was given. Retreatment 
was withheld in cases where preeclampsia or eclampsia developed (in which case open-label 
magnesium sulfate was administered for seizure prophylaxis), if it was thought that a delay 
in delivery in order to administer retreatment would be detrimental to the mother or the 
fetus, or if the gestational age was greater than 34 weeks. In a small number (n=14), the 
infusion was increased above 2 g per hour and these women were excluded from the 
analysis cohort. The management of women with PPROM (e.g., antibiotic use) was 
institution dependent.
The outcomes of interest in this study were delivery within 48 hours and delivery within 7 
days from randomization. Secondary outcomes included maternal outcomes and 
complications and neonatal outcomes. Neonatal outcomes included a composite of 
respiratory distress (RDS), interventricular hemorrhage (IVH grades 3 or 4), periventricular 
leukomalacia (PVL), sepsis, necrotizing enterocolitis (NEC), retinopathy of prematurity 
(ROP), or death (collected until hospital discharge).
Continuous variables were analyzed using the Wilcoxon rank sum test. Categorical variables 
were analyzed using the chi-square test or the Fisher's exact test where appropriate. The 
proportion of women in each study group remaining pregnant was compared using survival 
analysis with the log rank test used to assess for the difference between the survival curves. 
A p-value of < 0.05 was considered significant.
Results
A total of 2241 women were enrolled in the original BEAM study; 1925 (85.9%) presented 
with PPROM. After the exclusion criteria were applied, 1259 women met criteria for this 
secondary analysis. 621 (49.3 %) received magnesium and 638 (50.7 %) received placebo. 
Demographic characteristics of the cohort are shown in Table 1. As shown in Figure 1, there 
was no difference in the rates of delivery within 48 hours and 7 days from randomization 
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(latency) in women receiving magnesium sulfate and those receiving placebo (< 48 hours, 
22.2% vs 20.7%, p = 0.51; < 7 days, 55.4% vs 51.4%, p= 0.16). Median latency and 
gestational age at delivery were similar between groups (latency: median [interquartile range 
[6.0 days [2.4–13.8] and 6.6 days [2.4–15.1], p =0.29; gestational age: median [interquartile 
range] 30.4 weeks [28.0–31.9] and 30.1 weeks [27.9–31.9], p=0.54), as were the survival 
curves from randomization to delivery (p = 0.20), as shown in Figure 2. Among this cohort 
of women, 8.3% achieved 34 weeks gestation. The use of tocolytic medications after 
randomization was infrequent in either group 2.1% (magnesium) vs 1.7% (placebo), p = 
0.63. Rates of antepartum complications including placental abruption and chorioamnionitis 
were similar between the magnesium sulfate and placebo groups: 8.1% and 8.0%, 
respectively p =0.97), and 12.6% and 11.8%, respectively (p = 0.66). Rates of postpartum 
endometritis did not differ between groups (magnesium 5.8% vs. placebo 7.1%, p = 0.36). 
Composite neonatal outcomes did not differ between groups (Table 2). However, infants 
exposed to magnesium sulfate had significantly lower rates of IVH (grade 3 or 4) when 
compared with placebo (0.7% vs 2.2%, OR 0.31; 95% CI 0.10–0.96).
Discussion
Magnesium sulfate administration for neuroprotection in women with a singleton gestation 
with preterm premature rupture of membranes without labor before 32 weeks’ gestation had 
no significant impact on rate of delivery within 48 hours or 7 days of randomization. 
Antepartum maternal complications were not increased with magnesium exposure. 
Additionally, there were no differences in composite neonatal outcomes.
The rates of delivery within 48 hours and within 7 days from randomization are consistent 
with what has been reported in the literature. In a randomized double blind placebo 
controlled trial of ampicillin and erythromycin versus placebo in women with PPROM 
between 24–32 weeks, Mercer et al demonstrated rates of delivery within 48 hours and 
within 7 days of 27.3% and 55.5% in women who received antibiotic therapy.12 Christmas 
et al. performed a randomized controlled trial of ampicillin, gentamicin, and clindamycin in 
94 women who experienced preterm premature rupture of membranes between 20–34 
weeks. In this study, 58.3% of women who received antibiotic therapy delivered within 7 
days of randomization.13 While there is benefit to antibiotic therapy and corticosteroid 
administration in women who experience PPROM, our data support the preexisting 
literature suggesting these women remain at very high risk for delivery within 7 days.
Interestingly, maternal outcomes including chorioamnionitis and endometritis were lower in 
our study than previously reported by Mercer et al.12 In our study, the rate of 
chorioamnionitis was 12% which is nearly one half of the 23% reported in the women whom 
received ampicillin and erythromycin in the Mercer study. The rate of endometritis among 
the cohort of women in our study was 6.4%, which was also lower than the 11.8% reported 
in the Mercer study.12
The finding of decreased rates of IVH in those infants exposed to magnesium sulfate is of 
interest and provides additional support to the neuroprotective effects of antenatal 
magnesium sulfate exposure. However, previous studies evaluating magnesium sulfate 
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exposure and IVH have produced conflicting results.14–15 Mittendorf et al14 performed a 
randomized controlled trial of women in preterm labor to magnesium sulfate or placebo and 
found that infants diagnosed with IVH were born to mothers with higher serum ionized 
magnesium rates. These results provided speculation that magnesium sulfate at higher doses 
may interact with other factors that promote brain injury or may interfere with the newborn 
coagulation cascade and promote brain injury through platelet dysfunction. A case control 
study by Petrova et al15 found that in preterm infants born between 23–31 weeks’ gestation 
diagnosed with IVH, exposure to magnesium sulfate appeared to be protective (adjOR 0.47 
(95%CI 0.24–0.91). A direct comparison between our findings and the above studies must 
be interpreted with caution. Magnesium sulfate was not used as a ‘tocolytic’ and serum 
ionized magnesium levels were not evaluated.
The management of women with PPROM varies among obstetric providers and has evolved 
over the past 20 years. Previous estimates suggested that 1 in 3 providers administered 
tocolytic therapy in the setting of PPROM in the 1980s. In the mid 1990s, it appeared that 
tocolytic use after PPROM was increasing, with nearly 75% of clinicians in the U.S. and 
abroad either using or would consider using tocolytic therapy.6, 16–17
In a survey of 731 Fellows and Members of the Royal College of Obstetricians and 
Gynecologists of Australia and New Zealand, 75% of obstetricians administered tocolytic 
therapy after PPROM.15 Similarly, Ramsey et al., 6 in a survey of 1375 maternal fetal 
medicine specialists, found that tocolytic agents were used by 73% of subspecialists. 
Magnesium sulfate was the most commonly used tocolytic (98%) and tocolytic was 
generally used for 48 hours or less to allow for the benefits of corticosteroids. Tocolytic use 
in our study was proscribed by the study protocol other than oral terbutaline, but its use was 
infrequent. Given that recent literature does not find sufficient evidence to support the use of 
tocolytics in women with PPROM, this may also reflect a change in provider practice 
patterns.18
The limitations of our study warrant discussion. Our outcomes of delivery within 48 hours 
and 7 days were after randomization, not PPROM. These time frames were chosen based on 
previous studies of latency antibiotics in women with PPROM. Thus, given that the median 
gestational age from PPROM to enrollment was over 24 hours, these may not be applicable 
to current clinical practice, as magnesium sulfate administration is often begun shortly after 
admission along with the use of latency antibiotics and corticosteroid administration. As 
management of PPROM was institution dependent, antibiotic regimens for latency may have 
differed and obstetrical management, including timing of delivery was not uniform. We did 
not perform a post hoc power analysis, as this practice is not appropriate in the setting of a 
fixed sample size, such as in the case of secondary analyses.
Given that several studies have demonstrated its beneficial effects in reduction of cerebral 
palsy in preterm infants, the use of magnesium sulfate for neuroprotection is likely to 
increase and may be adopted as standard clinical practice, similar to the use of latency 
antibiotics and corticosteroid administration, especially in the setting of preterm premature 
rupture of membranes.8–10 We conclude that magnesium sulfate administration for fetal 
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neuroprotection does not increase the duration of latency in women with a singleton 
pregnancy whom experience PPROM without labor between 24–32 weeks’ gestation.
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Magnesium sulfate administration for neuroprotection does not prolong latency in 
women with preterm premature rupture of membranes between 24 and 31 6/7 weeks' 
gestation.
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Rates of delivery within 48 hours and 7 days from randomization among study group
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Survival curves illustrating proportion of women remaining pregnant after randomization.
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Table 1






Gestational age at randomization (weeks) 28.5 ± 2.3 28.3 ± 2.3 0.10
Time from rupture of membranes to randomization (hours)
Median
[Interquartile range]
25.3 [11.3, 57.0] 24.9 [11.7, 56.9] 0.92
Maternal age (years) 26.8 ± 6.4 26.1 ± 6.2 0.06
Maternal prepregnancy body mass index‡ 26.3 ± 6.7 26.6 ± 6.8 0.32
Race
   Black
   White
   Hispanic










Married (no/total number) (%) 324/620 (52.3%) 283/636 (44.5 %) 0.006
Educational level (years) 11.9 ± 2.4 11.9 ± 2.4 0.77
Nulliparous (%) 195/621 (31.4%) 213/638 (33.4%) 0.45
Smoking during pregnancy (%) 186/621 (30.0%) 182/638 (28.5%) 0.58
Prior preterm delivery 183/621 (29.5%) 187/638 (29.3%) 0.95
Antenatal corticosteroid administration 602/621 (96.9%) 622/638 (97.5%) 0.55
IQR interquartile range; SD standard deviation
*
Data presented as n (%) based on 1259 women at enrollment
†
χ2, Fisher’s exact, or Wilcoxon rank sum test.
‡
The body mass index is the weight in kilograms divided by the square of the height in meters. Values were available for 558 mothers in the 
magnesium sulfate group and 578 in the placebo group.
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Table 2







Birthweight (grams) Mean (SD) 1468 ± 542 1489 ± 583 p=0.76‡
5 min Apgar < 7 90/621 (14.5%) 103/636 (16.2%) 0.88 (0.65–1.19)
Composite outcome§ 339/605 (56.0%) 350/623 (56.2%) 0.99 (0.79–1.25)
Respiratory Distress Syndrome 285/620 (46.0%) 293/633 (46.3%) 0.99 (0.79–1.23)
Periventricular Leukomalacia 8/589 (1.4%) 14/602 (2.3%) 0.58 (0.24–1.39)
Interventricular Hemorrhage (Grade 3 or 4) 4/589 (0.7%) 13/602 (2.2%) 0.31 (0.10–0.96)
Culture proven sepsis 83/620 (13.4%) 88/633 (13.9%) 0.96 (0.69–1.32)
Necrotizing enterocolitis 50/620 (8.1%) 49/633 (7.7%) 1.05 (0.69–1.58)
Retinopathy of prematurity 109/620 (17.6%) 113/633 (17.9%) 0.98 (0.73–1.31)
Death 27/621 (4.4%) 31/638 (4.9) 0.89 (0.52–1.51)
SD standard deviation
*
Data presented as n (%) based on 1259 women at enrollment
†
Wilcoxon rank sum test
§
Included any of respiratory distress (RDS), periventricular leukomalacia (PVL), interventricular hemorrhage (IVH grades 3 or 4), culture proven 
sepsis, necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), or death (collected until hospital discharge)
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